Revolutionizing Drug Delivery with Exosome Technology
Esco Aster is excited to announce a partnership that highlights its commitment to advancing drug delivery technologies through exosomes. Esco Aster, a leading player in the cell and derivatives Contract Research, Development, and Manufacturing Organization (CRDMO), has signed a significant agreement with Shine-On Biomedical. This collaboration aims to push the boundaries of innovative treatments by focusing on an HLA-G targeting exosome drug delivery platform.
Supporting Shine-On Biomedical's Groundbreaking Program
Through this collaboration, Esco Aster will provide comprehensive CMC manufacturing support for Shine-On Biomedical's cutting-edge HLA-G targeted exosome program. Beginning in 2023, this partnership embarked on a journey that involves high-yield exosome development utilizing Esco Aster's specialized cell line platform. The process has yielded substantial technical reports, including updates on formulation development, exosome loading, and stability studies, all of which supported Shine-On's submission to the regulatory authorities.
Successful Progress and Regulatory Milestones
One of the remarkable achievements during this venture was the clearance of Shine-On's Investigational New Drug (IND) application by the U.S. FDA in the first quarter of 2025. This significant milestone underscores the effectiveness of the collaboration and the promising potential of Shine-On's proprietary product, known as SOB100, designed specifically for HLA-G targeting.
Setting New Standards in Exosome-Based Drug Delivery
Shine-On Biomedical’s SOB100 project represents a first-in-class exosome drug delivery carrier that stands out due to its focus on HLA-G targeting capabilities. This innovative approach has already passed the stringent IND review process set by the U.S. FDA and is currently progressing through a Phase I study. These advancements set the stage for Shine-On to explore wider applications of exosome technology in drug development, potentially transforming treatment paradigms.
Statement from Shine-On Biomedical
Hung-Che Chiang, General Manager of Shine-On Biomedical, expressed enthusiasm regarding the ongoing research. He stated that "preclinical studies have demonstrated encouraging biodistribution characteristics, which pave the way for further exploration of various payload types including small molecules, nucleic acids, and proteins.”
Advanced Solutions for Biopharmaceutical Development
In addition to the partnership on the HLA-G program, Esco Aster is proactive in offering Mitosis™ Enterprise Solutions. These solutions are designed to support future evaluations of single-use cGMP workflows within various medical institutions, further propelling the biopharmaceutical landscape. This commitment ensures that patient-centric innovations remain at the forefront of development.
Strengthening the Bioeconomy in Asia
This collaboration not only enhances Esco Aster's reputation but also establishes the company as Singapore’s first fully homegrown CRDMO, specializing in engineered cancer exosome development. Their capabilities span from creating specialized cell lines to GMP manufacturing, utilizing patented technology like the 3D Tide Motion™ bioreactor. This advanced approach allows for cost-effective operations by facilitating multiple conditioned media harvests within a single run.
Support for Asia-Pacific Innovators
Esco Aster's mission extends to supporting innovators across the Asia-Pacific region in their pursuit of biomanufacturing scale-up, market access, and commercialization. This region, with its vast economic potential, provides a fertile ground for new ideas in healthcare and biopharmaceuticals, estimated at around USD 10.5 trillion in GDP and home to approximately 2.6 billion people. Esco Aster leverages its network of medical centers and expert clinician-scientists to facilitate investigator-initiated trials and first-in-man studies. Australia, in particular, benefits from R&D incentives that lower costs, embodying the company’s mission to advance its "One World BioSolutions for One Health" vision.
Frequently Asked Questions
What is the focus of the partnership between Esco Aster and Shine-On Biomedical?
The partnership centers on developing an HLA-G targeting exosome drug delivery platform, which aims to enhance the efficiency and efficacy of drug therapies.
What is SOB100?
SOB100 is Shine-On Biomedical's proprietary exosome drug delivery carrier, which has successfully passed regulatory hurdles and is undergoing initial clinical trials.
How does Esco Aster contribute to the exosome development process?
Esco Aster provides comprehensive manufacturing and technical support, utilizing its patented technologies to ensure high-quality exosome production.
What advancements have been made in the HLA-G program?
Key milestones include clearance from the U.S. FDA for the IND application, indicating regulatory confidence in the program's potential.
How does Esco Aster support the bioeconomy in Asia?
By facilitating biomanufacturing and commercialization efforts, Esco Aster plays a vital role in enhancing healthcare innovation throughout the Asia-Pacific region.
